-
Patient centricity in drug innovation and packaging design to take centre stage at Connect in Pharma in Geneva this September
Talk from Roche engineer Tiffany McIntire will highlight opportunities for the pharma sector to reinvent packaging to be more focused on patient needs in areas such as medication taken orally London, United Kingdom, 31 May 2022 / Sciad Newswire / Easyfairs announces today that Tiffany McIntire, a Principal Human Factors Engineer at Roche, will be one of the keynote speakers…
-
New study highlights talent needed to grow the biosimilars sector
London, UK, 24th May 2022 / Sciad Newswire / The RSA Group, a leading life sciences executive search firm, has published the latest of its Talent Equity® Reports: Biosimilars 2022. The new report features interviews with leaders of biosimilars companies who give their unique insights into the challenges and opportunities facing this fast-growing sector and the leadership needed to…
-
BioMoti collaborates with global pharmaceutical company to develop ovarian cancer treatment and appoints Dr John Beadle as Chairman
London, UK, 19th May 2022 / Sciad Newswire / BioMoti Ltd today announces an agreement with a global pharmaceutical company to collaborate on the development of its lead ovarian cancer candidate, BMT101, to clinical phase 2a proof-of-concept. The collaboration agreement provides access to the partner company’s expertise including its proprietary commercial manufacturing technology and an option for the global pharmaceutical…
-
BRIM Biotechnology, Inc. and Ora, Inc. announce new partnership to accelerate the development of regenerative peptide therapy, BRM421, for Dry Eye Syndrome
Taipei, Taiwan, 17th May 2022 / Sciad Newswire / BRIM Biotechnology, Inc. (“BRIM”), a clinical-stage company developing novel regenerative therapies in ophthalmology, today announces it has entered into a new strategic partnership with Ora®, Inc. (“ORA”), the world’s leading ophthalmic research organization for the late-stage clinical development of lead drug candidate, BRM421, for dry eye syndrome (DES). BRIM intends to initiate Phase 3…
-
Domainex appoints Dr Scott Martin as Analytical and Bioanalytical Group Leader
Cambridge, UK, 12th May 2022 / Sciad Newswire / Domainex Ltd, a leading integrated medicines research services partner, is pleased to announce that Dr Scott Martin has been appointed Analytical and Bioanalytical Group Leader with immediate effect. His appointment will strengthen Domainex’s rapidly expanding team of international scientists and follows the announcement of Domainex’s purchase of over £1M worth of new…
-
Faculty Opinions makes the insights and article recommendations from its global network of life sciences and medical experts free-to-access
Faculty Opinions, an H1 community, opens up its content by providing free access to 235,000+ research article recommendations in its mission to expand and democratize access to the best recent research and the opinions of its global Faculty of experts from across life sciences and medicine. London, UK and New York, 10th May 2022 / Sciad Newswire / Faculty…
-
Egle Therapeutics appoints Pierre Legault as Chairman and Board Member
Paris, France, 5th May 2022 / Sciad Newswire / Egle Therapeutics SAS (Egle), an emerging biotechnology company dedicated to developing novel immunotherapies for oncology and autoimmune diseases, is pleased to announce Pierre Legault as Chairman and board member as of March 2022. With extensive experience over 35 years in leadership roles at leading companies across the biotech and pharmaceutical…
-
Rousselot® Biomedical announces the launch of Quali-Pure HGP 2000
Irving, United States, May 4 2022 / Sciad Newswire / Rousselot®, Darling Ingredients’ health brand and the global leader of collagen-based solutions1, launches Quali-Pure™ HGP 2000, a new endotoxin-controlled, pharmaceutical-grade gelatin specifically designed for vaccines and wound healing applications. As the latest addition to Rousselot Biomedical’s rapidly expanding product offering, this new non-gelling hydrolyzed gelatin further extends the scope of biomedical applications…
-
Watson-Marlow Fluid Technology Solutions and the National Institute for Bioprocessing Research and Training partner for biopharma training programme
Falmouth, UK, 3rd May 2022 / Sciad Newswire / Watson-Marlow Fluid Technology Solutions (WMFTS) today announces it has partnered with the National Institute of Bioprocessing Research and Training (NIBRT) to develop and deliver a combined in-person and online global biopharma training programme for employees. NIBRT is a world-class independent institute providing training and research solutions for the biopharmaceutical manufacturing industry….
-
New BHM® Anti-Viral Nasal Spray launches in Singapore
Designed to protect, capture and prevent the inhalation of infectious viruses, including SARS-CoV-2. Highlights: Birmingham, UK, 28th April 2022 / Sciad Newswire / Birmingham Biotech Ltd, an innovator in diagnostic tests, protective nasal sprays and mobile medical facilities, today announces the Singapore launch of its latest technology, BHM® Anti-Viral Nasal Spray, an easy-to-use nasal device with a unique…